A Prospective, Multicenter, Open-label, Post-Marketing Observational Study to Evaluate the Anti-Anginal Effectiveness of Trimetazidine 60 mg Once Daily Formulation in Stable Angina Patients in Real-World Practice - NA

Abbott Healthcare Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年7月22日

试验速览

暂无简介。

•The subjects will be included in the study based on the following criteria:
•1. Male/female of = 18 years of age.
•2. Patient diagnosed with CSA by HCP (health care professional) and Prescribed Trimetazidine 60 mg OD as per HCP’s discretion.
•3. Patient willing to give written informed consent to participate into the study.
•4. Willing to take the study drug as prescribed by the investigator.
•5. Willing to comply with the protocol requirements.

•A patient will be excluded from the study if they meet any of the following criteria:
•1. Known hypersensitivity to Trimetazidine or excipients of the formulation.
•2. Parkinson’s disease, parkinsonian symptoms, tremors, restless leg syndrome and other related movement disorders.
•3. Known case of severe renal impairment.
•4. Any other condition/ uncontrolled co-morbid conditions that, in the opinion of the investigator, does not justify the inclusion of the patient in the study.
•5. Pregnant and lactating females.

发起方